Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Glabellar Rhytides
Interventions: Preservative-free Saline, Mentor Purified Toxin; Drug
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Severe Hypertriglyceridemia
Interventions: Solbinsiran, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 29
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 24 more

Conditions: Specific Phobia
Interventions: Exposure therapy; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions: APL-9, Vehicle Control; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 16
States / cities: Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more

Conditions: Mental Health and General Well-being
Interventions: Miracle of Mind meditation, Neutral audio learning task; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Pain
Interventions: Ketamine; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Polycystic Ovary Syndrome
Interventions: Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound, Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe, Intrauterine insemination or timed intercourse; Drug · Diagnostic Test · Other
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Respiration Failure, Cardio Vascular Disease, Cardiogenic Pulmonary Oedema, Critical Illness, Mechanical Ventilation, Cardiogenic Shock, Cardiopulmonary
Interventions: Volume Controlled Mode, Pressure Controlled Mode; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections
Interventions: MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more

Conditions: PD Effects of GS-0976 (NDI-010976) on Fractional DNL
Interventions: GS-0976, Placebo, 1-13C acetate, Fructose solution; Drug · Other
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Volunteers
Interventions: PF-04427429; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Moderate and Severe Plaque Psoriasis
Interventions: Placebo, AEB071; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 10
States / cities: Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more

Conditions: Weight Loss
Interventions: VK2735, Placebo; Biological
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more

Conditions: Sexual Dysfunction, Major Depressive Disorder
Interventions: Vilazodone, Sertraline; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Charlottesville, Virginia

Conditions: Contraception
Interventions: Telephone message; Other
Lead sponsor: Planned Parenthood League of Massachusetts; Other
Eligibility: 18 Years and older · Female only
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo, 0.15% azelastine hydrochloride; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more

Conditions: Cardiac Surgery
Interventions: Human platelets; Biological
Lead sponsor: Cellphire Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 12 more

Conditions: Ulcerative Colitis
Interventions: NX-13 250mg, NX-13 750mg, NX-13 Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Miami, Florida • Orlando, Florida • Tampa, Florida + 8 more

Conditions: Healthy Volunteers
Interventions: Bendavia, Sterile saline (0.9%), Cigarette smoking; Drug · Other
Lead sponsor: Mighty Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: TTI-101, Placebo; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 40 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 28
States / cities: Birmingham, Alabama • La Jolla, California • Orange, California + 23 more

Conditions: COVID-19, Coronavirus, Coronavirus Infection
Interventions: INOpulse, Placebo; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more

Conditions: Pain, Dental Impaction
Interventions: Ketorolac tromethamine, Placebo; Drug
Lead sponsor: Egalet Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hidradenitis Suppurativa
Interventions: NovoSorb® BTM, Human Cadaveric Allograft; Device
Lead sponsor: Joseph M. Still Research Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Suicidal Ideation, Hopelessness, Wish to Live, Wish to Die
Interventions: Single-Session Mechanism-Focused Intervention (SSMFI), Distress Tolerance Skills Review; Behavioral
Lead sponsor: Shannon E. Sauer-Zavala; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

The Effects of Safety Seeking Behaviors During Exposure Therapy for Adults With Spider Phobia

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)

Sub-dissociative Dose Ketamine Dosing Study

Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole

COMPARE-VENT Feasibility Pilot Study

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects

First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

VK2735 for Weight Management Phase 2

Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?

Contraceptive Choice at the Time of Uterine Evacuation

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

A Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery

A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions

Randomized Controlled Trial of a Single-session Mechanism-focused Intervention for Suicidal Thoughts and Behaviors